Skip to main content
Partnerships
  1. Home
  2. Partnerships

HNCIG collaborates with academic institutions, cooperative clinical trial groups, regulatory agencies, and industry partners to advance research in head and neck cancer.

These partnerships support:

  • Development of innovative clinical trials
  • Access to new therapeutic agents
  • International research infrastructure
  • Funding for collaborative studies.

By working with a broad range of stakeholders, HNCIG ensures that research initiatives remain scientifically rigorous, clinically relevant, and globally accessible.

Impact of HNCIG Research

Since its creation, the Head and Neck Cancer International Group (HNCIG) has played an important role in advancing international collaboration and generating high-impact scientific evidence in head and neck oncology.

By bringing together cooperative clinical trial groups and research institutions from across the world, HNCIG has enabled studies that address critical clinical questions and contribute to the development of evidence-based treatment strategies.

Through multinational collaboration, the organisation has facilitated clinical trials, large-scale pooled analyses, and consensus initiatives that have influenced both clinical practice and future research directions.


The impact of HNCIG research can be seen in several key areas:

Advancing Clinical Evidence

HNCIG collaborative studies have helped generate robust data on treatment strategies in head and neck cancer, supporting evidence-based decision-making in areas such as radiotherapy, systemic therapy, and treatment de-escalation.

Large international trials involving multiple cooperative groups have provided insights that would not have been possible within single institutions or national networks.

The HNCIG Partnerships and Finance Committee are keen to expand links with companies involved in the treatment of and research into Head and Neck Cancer.  

Please contact secretariat@hncig.org for more information.